MOSCOW, March 10. /TASS/. A group of scientists plans to begin clinical trials of the first Russian monopreparatam on the basis of magnetite for the diagnosis of malignant tumors using MRI in 2018, reported TASS the head of project, head of laboratory “Biomedical nanomaterials” research technological University “MISIS”, doctor of chemical Sciences Alexander Mazhuga.
“At the successful completion of preclinical trials of 2018, we plan to begin clinical trials of the first domestic contrast agent for imaging of brain tumors. Developed technology is universal and can be used to diagnose other types of cancer,” said Dr..
A group of Russian scientists from National research technological University “MISIS”, Moscow state University named after Lomonosov and the Russian national research medical University (RNIMU) Pirogov with 2014 is developing diagnostic monopreparatam for the detection of cancer.
Russian scientists could create a drug, the average particle size of 40 nanometers. The particles contain magnetite, covered with a biopolymer. The magnetite nanoparticles are clearly visible on MRI images, giving doctors the ability to detect the tumor at early stages. The magnetite is non-toxic to the body, unlike other existing tools, Mazhuga said. In addition, the cost of this substance are significantly lower than other contrast agents.
In addition, this technology can be used for targeted transport of medication to tumor cells.
“We have developed a technology unparalleled in the world, which can be directed to release the drug in specified cancer cells,” said the project Manager.
The magnetite is coated with a special substance, which is a vector that feels the receptors on the surface of cancer cells. After it gets inside these cells and thus the drug acts only on tumor cells without exerting toxic effects on the whole body.Related posts: